Accuray Generated $55.6M in First Quarter Gross Orders; Revenue Increased 5 Percent Year over Year

Accuray today reported financial results for the first fiscal quarter ended September 30, 2017.

 
[24-October-2017]
 
 

SUNNYVALE, Calif., Oct. 24, 2017 /PRNewswire/ --Accuray Inc. today reported financial results for the first fiscal quarter ended September 30, 2017.

First Quarter Highlights

  • Gross orders increased 11 percent to $55.6 million, net orders were $51.0 million. Ending backlog increased 14 percent year-over-year to $465.0 million
  • Gross orders featured a strong contribution from TomoTherapy® and Radixact™ Systems that represented approximately 75 percent of unit mix
  • Revenue increased 5 percent year-over-year to $91.0 million driven by product revenue growth of 9 percent
  • Gross margin expanded approximately 600 basis points year-over-year to 42 percent driven by significant improvements in both product and service gross margins
  • Enhanced capital structure by reducing short term debt and potential share dilution by refinancing and extending convertible debt
  • Newly published 10-year study data demonstrated the clinical efficacy of the CyberKnife® System with low-risk prostate cancer that showed 98.4 percent of study participants had local disease control 10-years post treatment (1)

"Our 11 percent year-over-year gross orders growth during the first quarter was highlighted by Radixact system wins primarily in new and competitor bunkers," said Joshua H. Levine, president and chief executive officer. "Customers cite the precision, case mix versatility and speed of our systems as reasons for their decision to select Accuray. Our first quarter results are on track to achieving our growth objectives for the year and therefore we are reaffirming today the fiscal 2018 guidance we provided in August."

Financial Highlights

Gross product orders totaled $55.6 million for the 2018 fiscal first quarter compared to $50.3 million for the prior fiscal year period. Ending product backlog was $465.0 million, approximately 14 percent higher than backlog at the end of the prior fiscal year first quarter.

Total revenue was $91.0 million compared to $86.5 million in the prior fiscal year first quarter. Service revenue totaled $52.0 million compared to $50.9 million, while product revenue totaled $38.9 million compared to $35.6 million in the prior fiscal year first quarter. The increase in product revenue was primarily due to backlog conversion of orders to revenue from the EIMEA and Japan regions. Service revenue increased due to the continued install base expansion.

Total gross profit for the fiscal 2018 first quarter was $38.1 million or 42 percent of sales, comprised of product gross margin of 43 percent and service gross margin of 41 percent. This compares to total gross profit of $31.3 million or 36 percent of sales, comprised of product gross margin of 34 percent and service gross margin of 38 percent for the prior fiscal year fiscal first quarter. The increase in gross margin was due to several factors including: volume, product mix, intangible amortization expiring in the fourth quarter of prior year and cost down initiatives on both product and service cost of goods sold.

Operating expenses were $40.2 million, an increase of 6 percent compared with $37.9 million in the prior fiscal first quarter. The increase is primarily due to investments in research and development as well as sales and marketing. Fiscal 2018 operating expense is now anticipated to be 3 to 5 percent higher than fiscal 2017, which is a run rate of approximately $39 to $40 million per quarter.

Net loss was $9.4 million, or $0.11 per share, for the first quarter of fiscal 2018, compared to a net loss of $9.9 million, or $0.12 per share, for the first quarter of fiscal 2017. Net loss for the first quarter of fiscal 2018 included a $3.2 million non-cash early extinguishment of debt expense.

Adjusted EBITDA for the first quarter of fiscal 2018 was $3.2 million, compared to $1.2 million in the prior fiscal year first quarter.

Cash, cash equivalents, investments and short-term restricted cash were $94.4 million as of September 30, 2017 compared to $108.8 million as of June 30, 2017.

As previously announced in August 2017, the company enhanced its capital structure through the issuance of approximately $85.0 million of 3.75% convertible senior notes due July 2022 and concurrently retiring approximately $75.0 million of previously outstanding 3.50% convertible senior notes due February 2018.

2018 Financial Guidance

The company is reaffirming the revenue, adjusted EBITDA, and gross orders guidance provided on August 22, 2017 as follows:

  • Revenue: $390.0 million to $400.0 million representing growth of approximately 2 percent to 4 percent year-over-year with product revenue growing approximately 5 to 10 percent year-over-year;
  • Adjusted EBITDA: $25.0 million to $30.0 million representing growth of approximately 23 percent to 47 percent year-over-year; and
  • Gross Orders growth of approximately 5 percent.

Guidance for non-GAAP financial measures excludes amortization of intangibles, depreciation, stock-based compensation expense, interest expense, net and provision for income taxes. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Use of Non-GAAP Financial Measures" below.

Conference Call Information

Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss its fiscal first quarter results and recent corporate developments. Conference call dial-in information is as follows:

  • U.S. callers: (855) 867-4103
  • International callers: (262) 912-4764
  • Conference ID Number (U.S. and international): 98682556

Individuals interested in listening to the live conference call via the Internet may do so by logging on to Accuray's website, www.accuray.com. In addition, a taped replay of the conference call will be available beginning approximately two hours after the call's conclusion and available for seven days. The replay telephone number is (855) 859-2056 (USA) or (404) 537-3406 (International), Conference ID: 98682556. An archived webcast will also be available at Accuray's website.

Use of Non-GAAP Financial Measures

Accuray has supplemented its GAAP net loss with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation ("adjusted EBITDA"). Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the financial statement tables included in this press release, and investors are encouraged to review this reconciliation.

There are limitations in using this non-GAAP financial measure because it is not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies and excludes expenses that may have a material impact on the company's reported financial results. This non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations, including management's expectations regarding orders, backlog, revenues, adjusted EBITDA, operating expenses and run rates, ability to meet financial targets, and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: the company's ability to convert backlog to revenue; the timing of the China Class A license announcement; the success of the adoption of our CyberKnife, TomoTherapy, and Radixact Systems; the company's ability to manage its expenses; continuing uncertainty in the global economic environment; and other risks detailed from time to time under the heading "Risk Factors" in the company's Annual Report on Form 10-K, which was filed on August 25, 2017, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

             (1)    Katz A (September 09, 2017) Stereotactic Body
                     Radiotherapy for Low-Risk Prostate Cancer: A
                     Ten-Year Analysis. Cureus 9(9): e1668. DOI
                     10.7759/cureus.1668

Financial Tables to Follow

 

                         Accuray Incorporated

                Consolidated Statements of Operations

                (in thousands, except per share data)

                             (Unaudited)


                                                 Three Months Ended
                                                 September 30,
                                              -------------------

                                                   2017                  2016
                                                   ----                  ----


    Gross Orders                                $55,647               $50,335

    Net Orders                                   51,038                37,187

    Order Backlog                               464,968               407,487


    Net revenue:

    Products                                    $38,916               $35,599

    Services                                     52,034                50,907
                                                 ------                ------

    Total net revenue                            90,950                86,506

    Cost of revenue:

    Cost of products                             22,102                23,352

    Cost of services                             30,742                31,810
                                                 ------

    Total cost of
     revenue                                     52,844                55,162
                                                 ------                ------

    Gross profit                                 38,106                31,344

    Operating expenses:

    Research and
     development                                 14,093                12,229

    Selling and
     marketing                                   14,757                14,318

    General and
     administrative                              11,308                11,344

    Total operating
     expenses                                    40,158                37,891
                                                 ------                ------

    Loss from
     operations                                 (2,052)              (6,547)

    Other expense,
     net                                        (6,571)              (4,005)

    Loss before
     provision for
     income taxes                               (8,623)             (10,552)

    Provision for
     (benefit from)
     income taxes                                   759                 (626)
                                                    ---                  ----

    Net loss                                   $(9,382)             $(9,926)
                                                =======               =======


    Net loss per
     share -basic
     and diluted                                $(0.11)              $(0.12)
                                                 ======                ======

    Weighted average common shares used in
     computing loss per share:

    Basic and diluted                            83,747                81,576
                                                 ======                ======

 

                                   Accuray Incorporated

                                Consolidated Balance Sheets

                                      (in thousands)

                                        (Unaudited)


                                September 30,               June 30,

                                                 2017                      2017
                                                 ----                      ----

     Assets

     Current assets:

     Cash and cash equivalents                $67,916                   $72,084

     Investments                               23,931                    23,909

     Restricted cash                            2,547                    12,829

     Accounts receivable, net                  69,650                    72,789

     Inventories                              113,421                   105,054

     Prepaid expenses and other
      current assets                           16,909                    18,988

     Deferred cost of revenue                   2,497                     3,350

     Total current assets                     296,871                   309,003

     Property and equipment,
      net                                      21,672                    23,062

     Goodwill                                  57,863                    57,812

     Intangible assets, net                       929                       964

     Deferred cost of revenue                      74                       206

     Other assets                              16,543                    15,417

     Total assets                            $393,952                  $406,464
                                             ========                  ========

     Liabilities and equity

     Current liabilities:

     Accounts payable                         $22,199                   $17,486

     Accrued compensation                      20,813                    25,402

     Other accrued liabilities                 18,113                    23,870

     Short-term debt                           39,151                   113,023

     Customer advances                         19,364                    16,926

     Deferred revenue                          80,303                    87,785

     Total current liabilities                199,943                   284,492

     Long-term liabilities:

     Long-term other
      liabilities                              10,414                    10,068

     Deferred revenue                          16,080                    13,823

     Long-term debt                           118,869                    51,548

     Total liabilities                        345,306                   359,931

     Equity:

     Common stock                                  84                        84

     Additional paid-in
      capital                                 508,014                   496,887

     Accumulated other
      comprehensive income
      (loss)                                      316                      (52)

     Accumulated deficit                    (459,768)                (450,386)

     Total equity                              48,646                    46,533
                                               ------                    ------

     Total liabilities and
      equity                                 $393,952                  $406,464
                                             ========                  ========

 

                             Accuray Incorporated

    Reconciliation of GAAP Net Loss to Adjusted Earnings Before Interest, Taxes,
                                 Depreciation,

         Amortization and Stock-Based Compensation (Adjusted EBITDA)

                                (in thousands)

                                 (Unaudited)


                                            Three Months Ended
                                              September 30,
                                           -------------------

                                               2017                     2016
                                               ----                     ----

     GAAP net loss                         $(9,382)                $(9,926)

       Amortization
        of
        intangibles
        (a)                                      36                    1,988

       Depreciation
        (b)                                   2,478                    2,667

       Stock-based
        compensation
        (c)                                   2,432                    3,473

       Interest
        expense, net
        (d)                                   6,820                    3,592

       Provision for
        (benefit
        from) income
        taxes                                   759                    (626)

     Adjusted
      EBITDA                                 $3,143                   $1,168
                                             ======                   ======

    (a) consists of amortization of
     intangibles -developed technology
     and acquired patents.

    (b) consists of depreciation,
     primarily on property and equipment.

    (c) consists of stock-based
     compensation in accordance with ASC
     718.

    (d) consists primarily of interest
     income from available-for-sale
     securities, interest expense
     associated with our convertible
     notes and revolving credit facility
     and non-cash loss on extinguishment
     of debt.

 

                                       Accuray Incorporated

                                     Forward-Looking Guidance

                    Reconciliation of Projected Net Loss to Projected Adjusted
                    Earnings Before Interest, Taxes, Depreciation, Amortization
                           and Stock-Based Compensation (Adjusted EBITDA)

                                          (in thousands)

                                          (Unaudited)


                                         Twelve Months Ending
                                            June 30, 2018
                                            -------------

                                                 From                            To
                                                 ----                           ---

     GAAP
     net
     loss                                            $(20,600)                      $(15,600)

       Depreciation
       and
       amortization
       (a)                                              10,400                          10,400

       Stock-
       based
       compensation
       (b)                                              13,000                          13,000

       Interest
       expense,
       net
       (c)                                              19,000                          19,000

       Provision
       for
       income
       taxes                                             3,200                           3,200

     Adjusted
     EBITDA                                            $25,000                         $30,000
                                                       =======                         =======

    (a) consists of depreciation,
     primarily on property and equipment
     as well as amortization of
     intangibles -developed technology
     and acquired patents.

    (b) consists of stock-based
     compensation in accordance with ASC
     718.

    (c) consists primarily of interest
     income from available-for-sale
     securities, interest expense
     associated with our convertible
     notes and revolving credit facility
     and non-cash loss on extinguishment
     of debt.

 

     Doug Sherk                                      Beth Kaplan

     Investor Relations, EVC Group                   Public Relations Director, Accuray

                                   +1 (415) 652-9100                                   +1 (408) 789-4426

     dsherk@evcgroup.com                             bkaplan@accuray.com

 

 

View original content with multimedia:http://www.prnewswire.com/news-releases/accuray-generated-556-million-in-first-quarter-gross-orders-revenue-increased-5-percent-year-over-year-300542425.html

SOURCE Accuray Incorporated

 
 
Company Codes: NASDAQ-NMS:ARAY
 
MORE ON THIS TOPIC